Every 8-K that DarioHealth Corp. (DRIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DRIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRIO filings page.
DarioHealth Corp. (DRIO) reports that Lawrence Leisure has retired from its Board of Directors, effective September 2, 2026, for personal reasons. The company states that his decision to retire did not result from any disagreement regarding its operations, policies, or practices. The report is signed by Chief Financial Officer, Treasurer and Secretary Chen Franco‑Yehuda.
DarioHealth Corp. (DRIO) announced that Steven Nelson, its President and Chief Commercial Officer, will cease serving in that role effective September 1, 2026, and his employment will terminate on September 30, 2026 under a Separation Agreement. He will receive earned wages, accrued and unused vacation, continued health insurance coverage through September 30, 2026, and up to three months of COBRA premium reimbursement at $2,600 per month, subject to the agreement’s terms. Outstanding equity awards will remain governed by existing plans and agreements, with any unvested awards expiring upon termination. Nelson will assist with transition matters through December 31, 2026. In parallel, DarioHealth and Nelson entered into a Consulting Agreement, effective October 1, 2026, under which he will provide advisory and consulting services through December 31, 2027, unless ended earlier. As consideration, he will be granted 30,000 shares of restricted common stock, subject to Compensation Committee approval, vesting on the first anniversary of the grant date or earlier upon a Change in Control, with partial accelerated vesting if the consulting relationship is terminated by the company.
DarioHealth Corp. is conducting a registered direct offering of 3,454,559 shares of common stock (or common stock equivalents) at $6.80 per share, for aggregate gross proceeds of approximately $23.5 million before fees and expenses. The securities include 2,437,060 shares of common stock and pre-funded warrants to purchase 1,017,499 shares at $6.7999 per warrant.
Board member Dennis Matheis is purchasing 14,430 additional shares at $6.93 per share. The pre-funded warrants are immediately exercisable but have beneficial ownership limits that generally restrict any holder and its affiliates from exceeding 4.99% or 9.99% ownership without advance notice or, in some cases, shareholder approval.
A.G.P./Alliance Global Partners is acting as sole placement agent, earning a 6.0% cash fee on most gross proceeds (1.0% for certain investors) plus up to $60,000 of reimbursed expenses. For 30 days after closing, the company agreed not to issue most new equity or file additional registration statements, while retaining the ability to use its existing at-the-market facility. Net proceeds are intended for working capital, investments, acquisitions, and general corporate purposes.
DarioHealth Corp. reported that the temporary medical leave of absence of its President and Chief Commercial Officer, Steven Nelson, was extended on July 10, 2026 for an indefinite period. During his leave, the company states that his responsibilities are being handled by members of the senior management team.
DarioHealth Corp. has appointed veteran healthcare executive John R. Palumbo to its Board of Directors, effective April 10, 2026. Palumbo, age 75, has more than four decades of operating experience across early-stage ventures and large healthcare companies, including leadership roles at AmerisourceBergen, Allscripts and Shared Medical Systems.
He has guided organizations through transformative growth, including supporting two IPOs and major operational and commercial transformations, and currently serves on several healthcare and digital health boards. Dario expects his deep relationships with health systems, payers and senior healthcare executives to support its next phase of partner-led commercial scaling and expansion across payer, provider and health services markets.
DarioHealth Corp. entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market equity program allowing the company to issue and sell up to $20,000,000 of common stock from time to time. A.G.P. will act as sales agent or principal and receive a 3.00% commission on gross proceeds from share sales.
The shares are registered under DarioHealth’s effective Form S-3 shelf registration statement and related ATM prospectus supplement. The company may use net proceeds for commercial, sales and marketing activities, product research and development, mergers and acquisitions, repayment of indebtedness under its credit facility with Callodine Commercial Finance, LLC, and general working capital. DarioHealth can suspend or terminate the program at its discretion, and the agreement also includes customary indemnification, expense reimbursement caps, and termination rights.
DarioHealth Corp. amended its Certificate of Incorporation to give its Board of Directors express authority to alter and repeal the company’s bylaws, while keeping stockholders’ power to alter or repeal the bylaws as well. Stockholders approved this amended and restated charter at the annual meeting held on January 29, 2026.
DarioHealth Corp. held its 2026 Annual Meeting of Stockholders, where shareholders elected seven directors and ratified Kesselman & Kesselman as the independent auditor for the fiscal year ending December 31, 2026.
Stockholders approved several capital-related items, including ratifying the conversion of 25,605 shares of Series D, D-1, D-2 and D-3 Preferred Stock into 1,697,843 shares of common stock, the potential issuance of up to 679,137 dividend shares of common stock, and up to 208,754 additional common shares as consideration under lock-up agreements tied to prior preferred stock. They also ratified issuances of common stock upon exercise of pre-funded warrants, warrants and restricted stock units issued in connection with the Twill Inc. acquisition, increased the shares authorized under the 2020 Equity Incentive Plan by 500,000 shares, approved a non-binding advisory resolution on executive compensation, and amended the Certificate of Incorporation to grant the board authority to amend the bylaws.
DarioHealth Corp. amended its Callodine Loan Facility on November 5, 2025. The amendment resets financial covenants and waives financial‑covenant testing for the second and third quarters of 2025. It replaces the minimum cash covenant with a $10,000,000 minimum consolidated unencumbered liquid assets covenant and requires monthly 13‑week cash‑flow reporting when liquidity is below $11,000,000 (subject to an EBITDA exception). The lenders clarified that an additional $2,500,000 funding is uncommitted and at their discretion.
The exit fee increases by $150,000 (which may be waived if a change‑of‑control prepayment fee is triggered), and the Company paid a $150,000 amendment fee. In connection with the amendment, the lender warrants’ exercise price was reduced from $16.556 to $15.3495 per share, and the conversion price for up to $2,500,000 of the facility was reduced from $19.866 to $15.3495.
DarioHealth Corp. completed a private securities offering to accredited investors, selling 1,154,420 shares of common stock and pre-funded warrants to purchase up to 1,558,760 additional common shares at a purchase price of $6.45 per share or pre-funded warrant. The securities were issued in a transaction exempt from SEC registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
The company agreed to file a registration statement for the shares and the pre-funded warrant shares within 30 days after closing. Separately, DarioHealth amended and restated the certificate of designation for its Series C-1 preferred stock to accelerate mandatory conversion of all outstanding shares of that series into common stock, or at each holder’s election into pre-funded warrants, with holders also receiving accrued and unpaid dividends, subject to beneficial ownership blockers.
DarioHealth also announced that its board has begun a comprehensive strategic review to maximize shareholder value after receiving multiple unsolicited strategic inquiries. A special committee of independent directors was formed, and Perella Weinberg Partners was engaged as financial advisor to evaluate options including a sale, merger, strategic business combination, or continued standalone strategy.
DarioHealth Corp. (DRIO) filed an Form 8-K reporting amendments to multiple certificates of designation for its preferred stock series. The filing lists amended or restated certificates for Series A-1, C, C-2, D, D-1, D-2, and D-3 preferred shares and includes an interactive data cover page. The document also references written and soliciting communications under SEC Rules 425, 14a-12, 14d-2(b), and 13e-4(c). The filing is dated September 18–19, 2025 and notes the company’s common stock trades on NASDAQ Capital Market. The filing text lists exhibits but does not disclose the economic or governance terms of the amended designations within the provided excerpt.
DarioHealth Corp. filed an 8-K dated August 25, 2025 disclosing a Certificate of Amendment to its Certificate of Incorporation to implement a reverse stock split. The filing lists a press release dated August 25, 2025 and confirms submission of an interactive XBRL cover page. The document names the company's registered common stock (par value $0.0001) and the trading symbol DRIO on The Nasdaq Capital Market LLC, and is signed by the Chief Financial Officer, Treasurer and Secretary, Chen Franco-Yehuda.